-
ASC40 combined with bevacizumab was approved for clinical treatment of rGBM patients
Time of Update: 2021-06-11
Gale Pharmaceuticals announced today that after communication with the National Medical Products Administration of China, the clinical trial application of ASC40 combined with bevacizumab for the treatment of patients with recurrent glioblastoma (rGBM) has been accepted.
-
Prices of these Chinese medicinal materials have risen under the epidemic
Time of Update: 2021-06-11
On the other hand, under the impact of a large amount of low-priced imported turmeric, Chinese pharmaceutical companies' demand for Sichuan turmeric has decreased, and production capacity has been affected.
-
Huizhi Miao Tianxiang, Bayer Jiangwei both retired, Eli Lilly, and GSK have changed
Time of Update: 2021-06-11
At the same time, Bayer announced that starting from July 1, 2021, Chen Ying, the current senior vice president of the Bayer Group's prescription drug division and head of the China market, will take over Zhou Xiaolan as the president of the prescription drug division of the Asia-Pacific region.
-
The latest list of pharmaceutical companies announced: Qilu, Kelun, CSPC...
Time of Update: 2021-06-11
On January 29, Qilu Pharmaceutical was approved for the production of metformin and vildagliptin tablets for generic 4 types of applications and was deemed to have been reviewed, becoming the first imitation in China.
-
Sichuan pharmaceutical company will win the blockbuster first to imitate the $1.4 billion variety to welcome the first production company
Time of Update: 2021-06-11
Recently, the first generic drug R&D welcome progress: Hainan Simcere is the first to submit a generic drug listing application for idoxaban tosylate tablets, and Sichuan Pride Times Pharmaceuticals uses generic 3 types of telmisartan and amlodipine tablets for production Enter the stage of administrative approval.
-
Yiling Pharmaceutical Xiaoer Lianhua Qinggan Granules Obtained Clinical Approval
Time of Update: 2021-06-11
On June 2, Yiling Pharmaceutical issued an announcement and received a notice of drug clinical trial approval for Xiaoerlianhua Qinggan Granules approved and issued by the National Medical Products Ad
-
Researchers unlock the genetic map and adaptive genetic evolution of East Asian populations in the Ice Age
Time of Update: 2021-06-11
3. The earliest East Asian paleo-northern population appeared at the end of the Last Glacial MaximumTo further explore how climate change during the Last Glacial Maximum affects the populations of northern East Asia, the researchers analyzed the ancient genomes of AR19K individuals that lived at the end of the Last Glacial Maximum, 19,000 years ago.
-
Analyze 20,000 proteins to find probes
Time of Update: 2021-06-11
Finding highly active and selective small molecule ligands for 20,000 proteins in 15 years is a basically impossible goal.
-
Cefixime tablets, a subsidiary of General Pharmaceuticals, passed the consistency evaluation of generic drugs
Time of Update: 2021-06-11
received the "Approval for Supplementary Drug Application" for cefixime tablets approved and issued by the National Medical Products Administration.
Cefixime tablets belong to the category B national medical insurance catalog products.
612 million and RMB 2.
-
Zhendong Pharmaceutical’s "Bald Ran" regrets killing the crazy medical beauty track, which other pharmaceutical companies have entered the game?
Time of Update: 2021-06-11
Its anti-hair loss product, Feixin Minoxidil Liniment, has suddenly sold out (sales in the first quarter) Reached 50 million yuan, the second quarter is expected to have a great increase), it is still the concept of medical beauty, so I decided to keep it!Not only will Ante Pharmaceutical "turn waste into treasure"!
-
Zuoli Pharmaceutical: Esomeprazole Sodium for Injection Obtained Drug Registration Approval
Time of Update: 2021-06-11
On June 1, Zuoli Pharmaceutical announced that the company has recently received the "Drug Registration Certificate" for Esomeprazole Sodium for Injection approved and issued by the National Medical Products Administration.
The drug has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog" (2020 Edition) Class B drugs.
-
How to change the payment method for outpatient services from the post-payment system to the pre-payment system?
Time of Update: 2021-06-11
According to the "Opinions", the content of the reform of mutual aid security for outpatient medical insurance for employees can be summarized as "one decrease, one increase, one build and one adjustment", that is, to reduce the funds allocated to personal accounts and increase the investment of outpatient mutual aid protection; establish general outpatient medical expenses Coordinate the guarantee mechanism and adjust the scope of use of personal accounts .
-
Hisun Pharmaceutical: Moxifloxacin Hydrochloride Tablets Obtained Drug Registration Certificate
Time of Update: 2021-06-11
The company moxifloxacin hydrochloride tablets according to the new Class 4 State Food and Drug Administration approved for marketing, as if by conformance assessment.
On October 27, 2017, the State Food and Drug Administration accepted the company's application for drug registration for moxifloxacin hydrochloride tablets.
-
The first imitation base drug of Ivabradine tablets has been approved for marketing!
Time of Update: 2021-06-11
On May 25, 2021, CDE data showed that the ivabradine hydrochloride tablets (National Medicines Standard H20213404) declared by Beijing Baiao Pharmaceutical Co.
At the same time, data from Meinenet showed that the sales of ivabradine hydrochloride tablets in China's public medical institutions increased by 705.
-
The CEO and CFO of Hanhui Pharmaceutical have changed
Time of Update: 2021-06-11
Since June 1, Li Yan stepped down as the CEO of Hanhui Pharmaceuticals and was replaced by Hu Zhiqiang, reporting to the company’s chairman Liu Qi. According to Dami’s understanding, today Hanhui Pharmaceutical also announced a number of personnel changes in important positions, including Yu Tieming’s resignation as the company’s chief financial officer, Li Hao’s succession, and the appointment of He Dong as the vice president of the National Commercial and Diversified Business Department.
-
Nat Med: For the first time in humans, it has been confirmed that optogenetics can restore part of the vision of blind patients
Time of Update: 2021-06-11
The relevant research results were published online in the journal Nature Medicine on May 24, 2021, with the title of the paper "Partial recovery of visual function in a blind patient after optogenetic therapy".
-
Major clinical progress of global new tumor drugs April 2021
Time of Update: 2021-06-11
CheckMate-648, a phase 3 trial of nivolumab for the first-line treatment of esophageal squamous cell carcinoma, reached the primary and secondary clinical endpointsOn April 8, BMS announced that the Phase III clinical study code-named CheckMate -648 had achieved positive results.
-
What breakthroughs are behind the 40 years of sharpening the sword and conquering the famous "unable to medicine" target
Time of Update: 2021-06-11
"Hurry up" and deliver innovative therapies to patients"Hurry up" and deliver innovative therapies to patientsAfter Professor Shokat revealed the crystal structure of the KRAS mutant's new binding "pocket" in the journal Nature, a number of biomedical companies have invested in drug research and development along this direction.
-
Simcere Pharmaceutical's "Idoxaban Toluenesulfonate Tablets" Declared for Listing
Time of Update: 2021-06-11
On June 2, the Insight database showed that Hainan Simcere Pharmaceutical’s application for the listing of 4 types of generic drug idoxaban tosylate tablets was accepted (acceptance number: CYHS2101233/4/5) for the treatment of stroke and atrial fibrillation To prevent systemic embolism, it is the first domestic producer of this species.
-
Pan Guangcheng resigned as independent director of Kailaiying
Time of Update: 2021-06-11
On June 1, Kailaiying issued an announcement stating that it had recently received a written resignation report from independent director Pan Guangcheng.
Pan Guangcheng applied for the resignation of the company's independent director, strategic committee member, and nomination committee member.
